X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
hematology (84) 84
humans (79) 79
index medicus (72) 72
medical and health sciences (58) 58
medicin och hälsovetenskap (58) 58
clinical medicine (50) 50
klinisk medicin (50) 50
female (42) 42
male (42) 42
hematologi (41) 41
chronic myeloid leukemia (38) 38
middle aged (38) 38
adult (35) 35
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (30) 30
oncology (30) 30
aged (29) 29
imatinib (26) 26
dasatinib (25) 25
leukemia (25) 25
3122 cancers (24) 24
mutation (23) 23
chronic myelogenous leukemia (22) 22
cancer (20) 20
hemic and lymphatic diseases (18) 18
immunology (18) 18
protein kinase inhibitors - therapeutic use (18) 18
analysis (17) 17
expression (17) 17
tyrosine (17) 17
abridged index medicus (16) 16
leukemia, myelogenous, chronic, bcr-abl positive - pathology (16) 16
t-cells (16) 16
antineoplastic agents - therapeutic use (15) 15
care and treatment (15) 15
chronic myeloid-leukemia (15) 15
cml (15) 15
tyrosine kinase inhibitor (15) 15
3111 biomedicine (14) 14
bcr-abl (14) 14
genetic aspects (14) 14
leukemia, large granular lymphocytic - genetics (14) 14
leukemia, myelogenous, chronic, bcr-abl positive - immunology (14) 14
lymphocytes (14) 14
lymphocytes t (14) 14
article (13) 13
interferon (13) 13
patients (13) 13
pyrimidines - therapeutic use (13) 13
therapy (13) 13
cancer and oncology (12) 12
cancer och onkologi (12) 12
flow cytometry (12) 12
imatinib mesylate (12) 12
treatment outcome (12) 12
young adult (12) 12
activation (11) 11
chronic-phase (11) 11
leukemia, myelogenous, chronic, bcr-abl positive - genetics (11) 11
stat3 transcription factor - genetics (11) 11
cd8 antigen (10) 10
immune system (10) 10
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (10) 10
medicine (10) 10
phosphorylation (10) 10
protein-tyrosine kinase (10) 10
research (10) 10
adolescent (9) 9
apoptosis (9) 9
cell biology (9) 9
dasatinib therapy (9) 9
disease (9) 9
mice (9) 9
multidisciplinary sciences (9) 9
myeloid leukemia (9) 9
phenotype (9) 9
prognosis (9) 9
t cells (9) 9
aged, 80 and over (8) 8
animals (8) 8
bone marrow (8) 8
fusion proteins, bcr-abl - genetics (8) 8
gene expression (8) 8
in-vitro (8) 8
kinases (8) 8
medicine, research & experimental (8) 8
nk-cells (8) 8
piperazines - therapeutic use (8) 8
science (8) 8
stem-cells (8) 8
survival (8) 8
benzamides (7) 7
cells (7) 7
follow-up (7) 7
interferon-alpha (7) 7
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (7) 7
nilotinib (7) 7
nk cells (7) 7
pathogenesis (7) 7
thiazoles - therapeutic use (7) 7
transcription (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 08/2018, Volume 132, Issue 9, pp. 880 - 881
In this issue of Blood, Branford et al report that somatic variants other than BCR-ABL1 are frequently found in patients with newly diagnosed chronic myeloid... 
HEMATOLOGY | THERAPY | CHRONIC MYELOID-LEUKEMIA | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Mutation | Genomics | Humans
Journal Article
Journal Article
Journal of Allergy and Clinical Immunology, The, ISSN 0091-6749, 2017, Volume 140, Issue 3, pp. 782 - 796
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2012, Volume 366, Issue 20, pp. 1905 - 1913
Journal Article
Nature Genetics, ISSN 1061-4036, 2014, Volume 46, Issue 8, pp. 812 - 814
Journal Article
Nature Medicine, ISSN 1078-8956, 06/2017, Volume 23, Issue 6, pp. 692 - 702
Journal Article
The Lancet Oncology, ISSN 1470-2045, 06/2018, Volume 19, Issue 6, pp. 747 - 757
Tyrosine kinase inhibitors (TKIs) have improved the survival of patients with chronic myeloid leukaemia. Many patients have deep molecular responses, a... 
SURVIVAL | MAJOR MOLECULAR RESPONSE | TREATMENT-FREE REMISSION | ONCOLOGY | IMATINIB DISCONTINUATION | DISEASE | FOLLOW-UP | DASATINIB | WITHDRAWAL SYNDROME | NILOTINIB | PHASE-2 TRIAL | Predictive Value of Tests | Prospective Studies | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Time Factors | Antineoplastic Agents - adverse effects | Clinical Decision-Making | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Polymerase Chain Reaction | Adult | Female | Biomarkers, Tumor - antagonists & inhibitors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Drug Administration Schedule | Risk Assessment | Europe | Risk Factors | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Progression-Free Survival | Fusion Proteins, bcr-abl - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Antimitotic agents | Tyrosine | Antineoplastic agents | Analysis | Life Sciences | Hematology | Human health and pathology | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Cancer Research, ISSN 0008-5472, 05/2018, Volume 78, Issue 9, pp. 2407 - 2418
The molecular pathways that drive cancer progression and treatment resistance are highly redundant and variable between individual patients with the same... 
NETWORK | ONCOLOGY | SYNERGY | EX-VIVO PLATFORM | SENSITIVITY | INHIBITOR | MEDICINE | IDENTIFICATION | CLINICAL-RESPONSE | CANCER | REVEALS | Bcl-2 protein | Leukemia | Customizing | Crosstalk | Lymphocytes T | Drug screening | Patients | Molecular chains | Case studies | Learning algorithms | Pathways | Tacrolimus | Rewiring | Computer applications | Machine learning | Predictions | Combinatorial analysis | Cancer
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2013, Volume 8, Issue 1, p. e55818
Immunotherapy (eg interferon alpha) in combination with tyrosine kinase inhibitors is currently in clinical trials for treatment of chronic myeloid leukemia... 
CHRONIC MYELOGENOUS LEUKEMIA | CANCER-PATIENTS | B7-H1 PD-L1 | TUMOR BURDEN | MULTIDISCIPLINARY SCIENCES | HEPATOCELLULAR-CARCINOMA PATIENTS | IMATINIB | INTERLEUKIN-2 RECEPTOR | PHASE-I | T-CELLS | CLINICAL-SIGNIFICANCE | Antigens, CD34 - metabolism | Humans | Middle Aged | Arginase - metabolism | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Young Adult | Lymphocyte Activation - immunology | T-Lymphocytes - metabolism | Myeloid Cells - immunology | Adult | Female | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology | Interleukin-2 Receptor alpha Subunit - blood | Programmed Cell Death 1 Receptor - metabolism | Gene Expression Regulation, Leukemic | B7-H1 Antigen - metabolism | Interleukin-2 Receptor alpha Subunit - metabolism | Adolescent | Cell Line, Tumor | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Myeloid Cells - metabolism | T-Lymphocytes - immunology | Aged | Programmed Cell Death 1 Receptor - genetics | Medical research | Care and treatment | Immunotherapy | Medicine, Experimental | Development and progression | Interferon | Chronic myeloid leukemia | T cells | Risk factors | Cancer | Cell proliferation | Disease | PD-1 protein | Laboratories | Leukemia | Science | Clinical trials | Risk | Arginase | Lymphocytes T | Kinases | Suppressor cells | Ethics | Immunology | Interleukin 2 | Lymphocytes | Cell cycle | CD25 antigen | Protein-tyrosine kinase | Immune system | Tyrosine | CD34 antigen | Myeloid cells | Cytokines | Hematology | Secretion | Myeloid leukemia | Mortality | Blood banks | Patients | Studies | Pathology | Hospitals | Medical prognosis | PD-L1 protein | Stem cells | Ligands | Death | Lymphomas | Apoptosis | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Scientific Reports, ISSN 2045-2322, 12/2019, Volume 9, Issue 1, pp. 4275 - 15
Treating cartilage injuries and degenerations represents an open surgical challenge. The recent advances in cell therapies have raised the need for a potent... 
CELLS | REPAIR | PROTEIN | ARTICULAR-CARTILAGE | SAFETY | MULTIDISCIPLINARY SCIENCES | GENE-THERAPY | INFANT CHONDROCYTES | BONE | EXPRESSING TRANSFORMING GROWTH-FACTOR-BETA-1 | JOINT INJURY | Cell culture | Hyaluronan | Hydrogels | Chondrocytes | Polydactyly | Heparin | Hyaluronic acid | Chondrogenesis | Gene therapy | Joint diseases | Osteoarthritis | Cartilage diseases
Journal Article